Core Viewpoint - The company has successfully localized its AI-driven antibody drug development platform, enhancing collaboration with its core business, the "Thousand Mice and Ten Thousand Antibodies" initiative [1] Group 1: Company Developments - The company’s stock has seen a significant increase, rising nearly 7% and currently trading at 39.72 HKD with a transaction volume of 28.32 million HKD [1] - The localization of the AI platform aims to build an intelligent system for antibody drug development, which is expected to improve efficiency in preclinical PCC molecule development for global pharmaceutical partners [1] Group 2: Strategic Initiatives - The integration of the "Thousand Mice and Ten Thousand Antibodies" plan with the AI system is ongoing, which will provide pharmaceutical companies with more efficient research tools and a richer library of antibody molecules [1] - This strategic move is anticipated to propel the antibody discovery business into a new phase of development [1]
百奥赛图-B再涨近7% 公司已完成AI驱动抗体药物研发平台的本地化部署